Inc. (NASDAQ:INCR) Files An 8-K Other Events
ITEM 8.01. OTHER EVENTS
Our website at www.socialnetwork.ai is our recognized channel of distribution to post important information to shareholders and investors, including social media channel posts and a bi-weekly podcast.
Social Life Network, Inc. – Podcast Schedule for April and May 2021
Our Podcast schedule for April and May 2021 appears below with the link that each may be accessed at:
April 15th (Thursday @ 4PM Pacific / 7PM Eastern) – HuntPost.com, Inc. & WEnRV.com @ https://SocialNetwork.ai/podcast
April 19th (Monday @ 4PM Pacific / 7PM Eastern) – Social Life Network, Inc. @ https://SocialNetwork.ai/podcast
April 22nd (Thursday @ 4PM Pacific / 7PM Eastern) – LikeRE.com, Inc. @ https://SocialNetwork.ai/podcast
April 26th (Monday @ 4PM Pacific / 7PM Eastern) – MjLink.com, Inc. @ https://SocialNetwork.ai/podcast
April 28th (Wednesday @ 4PM Pacific / 7PM Eastern) – HuntPost.com, Inc. & WEnRV.com @ https://SocialNetwork.ai/podcast
May 3rd (Monday @ 4PM Pacific / 7PM Eastern) – Social Life Network, Inc. @ https://SocialNetwork.ai/podcast
May 6th (Thursday @ 4PM Pacific / 7PM Eastern) – LikeRE.com, Inc. @ https://SocialNetwork.ai/podcast
May 10th (Monday @ 4PM Pacific / 7PM Eastern) – MjLink.com, Inc. @ https://SocialNetwork.ai/podcast
May 13th (Thursday @ 4PM Pacific / 7PM Eastern) – HuntPost.com, Inc. & WEnRV.com @ https://SocialNetwork.ai/podcast
May 17th (Monday @ 4PM Pacific / 7PM Eastern) – Social Life Network, Inc. @ https://SocialNetwork.ai/podcast
May 20th (Thursday @ 4PM Pacific / 7PM Eastern) – LikeRE.com, Inc. @ https://SocialNetwork.ai/podcast
About Inc. (NASDAQ:INCR)
INC Research Holdings, Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company operates through two segments: Clinical Development Services and Phase I Services. The Company’s Clinical Development Services segment offers all clinical development services, including full-service global studies, as well as ancillary services, such as clinical monitoring, investigator recruitment, patient recruitment, data management, study reports to assist customers with their drug development process, quality assurance audits and specialized consulting services. The Company’s Phase I Services segment focuses on clinical development services for Phase I trials, which include scientific exploratory medicine, first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds.
